Regulation and Mechanism of Deleted in Breast Cancer-1 on Dendritic Cell Function in Systemic Lupus Erythematosus

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organs and involving both innate and adaptive immunity. Dendritic cells (DCs) play a crucial role in linking innate and adaptive immune responses, and therefore they deeply participate in the initiation and development of SLE. Deleted in breast cancer-1 (DBC1) is a negative regulator of deacetylase SIRT1 (the mammalian homolog of silent information regulator 1) and involves in tissue inflammation. Roles of DBC1 in immune cells remain largely unknown, especially in DCs. We here identified that DBC1 is upregulated in activated DCs, and DBC1 deficiency weakened DC maturation while promoting B7-H1 expression. DC conditional knockout of DBC1 ameliorated murine lupus pathology by decreasing autoantibodies, complement C3, plasma cells, and follicular T helper (Tfh) cells, whereas promoting regulatory T-cell development. We further demonstrated that Dbc1^-/- DC lowered proinflammatory cytokine secretion such as IL-4, IL-6, and IL-12, and reduced signal transducer and activator of transcription 5 (STAT5) signal. With STAT5 overexpression, the protective effect by Dbc1^-/- DC was abolished in the lupus model. Therefore, targeting the DBC1-STAT5 axis in DCs diversifies the therapeutic strategies for SLE.

Keywords

autoimmune disease / deleted in breast cancer-1 / dendritic cells / STAT5 / systemic lupus erythematosus

References

[1] A. Kaul, C. Gordon, M. K. Crow, et al., “Systemic lupus Erythematosus,” Nature Reviews Disease Primers 2 (2016): 16039.

[2] G. C. Tsokos, “Systemic Lupus Erythematosus, ”New England Journal of Medicine 365, no. 22 (2011): 2110–2121.

[3] C. C. Mok and C. S. Lau, “Pathogenesis of Systemic Lupus Erythematosus,” Journal of Clinical Pathology 56, no. 7 (2003): 481–490.

[4] Z. X. Xiao, N. Olsen, and S. G. Zheng, “The Essential Role of Costimulatory Molecules in Systemic Lupus Erythematosus,” Lupus 28, no. 5 (2019): 575–582.

[5] E. Pieterse and J. van der Vlag, “Breaking Immunological Tolerance in Systemic Lupus Erythematosus,” Frontiers in Immunology 5 (2014): 164.

[6] Z. X. Xiao, J. S. Miller, and S. G. Zheng, “An Updated Advance of Autoantibodies in Autoimmune Diseases,” Autoimmunity Reviews 20, no. 2 (2021): 102743.

[7] M. Xipell, G. M. Lledó, A. C. Egan, et al., “From Systemic Lupus Erythematosus to Lupus Nephritis: The Evolving Road to Targeted Therapies,” Autoimmunity Reviews 22, no. 10 (2023): 103404.

[8] R. Lu, M. E. Munroe, J. M. Guthridge, et al., “Dysregulation of Innate and Adaptive Serum Mediators Precedes Systemic Lupus Erythematosus Classification and Improves Prognostic Accuracy of Autoantibodies,” Journal of Autoimmunity 74 (2016): 182–193.

[9] J. C. Crispin and J. Alcocer-Varela, “The Role Myeloid Dendritic Cells Play in the Pathogenesis of Systemic Lupus Erythematosus,” Autoimmunity Reviews 6, no. 7 (2007): 450–456.

[10] V. S. Chan, Y. J. Nie, N. Shen, S. Yan, M. Y. Mok, and C. S. Lau, “Distinct Roles of Myeloid and Plasmacytoid Dendritic Cells in Systemic Lupus Erythematosus,” Autoimmunity Reviews 11, no. 12 (2012): 890–897.

[11] L. J. Jara, G. Benitez, and G. Medina, “Prolactin, Dendritic Cells, and Systemic Lupus Erythematosus,” Autoimmunity Reviews 7, no. 3 (2008): 251–255.

[12] P. Blanco, A. K. Palucka, M. Gill, V. Pascual, and J. Banchereau, “Induction of Dendritic Cell Differentiation by IFN-Alpha in Systemic Lupus Erythematosus,” Science 294, no. 5546 (2001): 1540–1543.

[13] J. Liu, X. Zhang, and X. Cao, “Dendritic Cells in Systemic Lupus Erythematosus: From Pathogenesis to Therapeutic Applications,” Journal of Autoimmunity 132 (2022): 102856.

[14] Z. X. Xiao, X. Zheng, L. Hu, J. Wang, N. Olsen, and S. G. Zheng, “Immunosuppressive Effect of B7-H4 Pathway in a Murine Systemic Lupus Erythematosus Model,” Frontiers in Immunology 8 (2017): 1765.

[15] X. Zheng, Z. X. Xiao, L. Hu, X. Fang, L. Luo, and L. Chen, “Dendritic Cell-Associated B7-H3 Suppresses the Production of Autoantibodies and Renal Inflammation in a Mouse Model of Systemic Lupus Erythematosus,” Cell Death & Disease 10, no. 6 (2019): 393.

[16] Z. X. Xiao, X. Hu, X. Zhang, Z. Chen, J. Wang, and K. Jin, “High Salt Diet Accelerates the Progression of Murine Lupus Through Dendritic Cells via the p38 MAPK and STAT1 Signaling Pathways,” Signal Transduction and Targeted Therapy 5, no. 1 (2020): 34.

[17] R. Venkatadri, V. Sabapathy, M. Dogan, and R. Sharma, “Targeting Regulatory T Cells for Therapy of Lupus Nephritis,” Frontiers in Pharmacology 12 (2021): 806612.

[18] R. A. Furie, R. F. van Vollenhoven, K. Kalunian, et al., “Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus,” New England Journal of Medicine 387, no. 10 (2022): 894–904.

[19] R. Furie, V. P. Werth, J. F. Merola, et al., “Monoclonal Antibody Targeting BDCA2 Ameliorates Skin Lesions in Systemic Lupus Erythematosus,” Journal of Clinical Investigation 129, no. 3 (2019): 1359–1371.

[20] H. J. Kim, S. J. Moon, and J. H. Kim, “Mechanistic Insights Into the Dual Role of CCAR2/DBC1 in Cancer,” Experimental & Molecular Medicine 55, no. 8 (2023): 1691–1701.

[21] J.-E. Kim, J. Chen, and Z. Lou, “DBC1 is a Negative Regulator of SIRT1,” Nature 451, no. 7178 (2008): 583–586.

[22] M. Magni, G. Buscemi, and L. Zannini, “Cell Cycle and Apoptosis Regulator 2 at the Interface Between DNA Damage Response and Cell Physiology,” Mutation Research Reviews in Mutation Research 776 (2018): 1–9.

[23] A. M. Trauernicht, S. J. Kim, N. H. Kim, and T. G. Boyer, “Modulation of Estrogen Receptor Alpha Protein Level and Survival Function by DBC-1,” Molecular Endocrinology 21, no. 7 (2007): 1526–1536.

[24] J. E. Kim, J. Chen, and Z. Lou, “p30 DBC Is a Potential Regulator of Tumorigenesis,” Cell Cycle 8, no. 18 (2009): 2932–2935.

[25] S. Kong, H. Dong, J. Song, et al., “Deleted in Breast Cancer 1 Suppresses B Cell Activation Through RelB and Is Regulated by IKKα Phosphorylation,” Journal of Immunology 195, no. 8 (2015): 3685–3693.

[26] Y. Gao, J. Tang, W. Chen, Q. Li, J. Nie, and F. Lin, “Inflammation Negatively Regulates FOXP3 and Regulatory T-Cell Function via DBC1,” Proceedings of the National Academy of Sciences of the United States of America 112, no. 25 (2015): E3246–3254.

[27] W. Zhang, W. Xu, and S. Xiong, “Macrophage Differentiation and Polarization via Phosphatidylinositol 3-Kinase/Akt-ERK Signaling Pathway Conferred by Serum Amyloid P Component,” Journal of Immunology 187, no. 4 (2011): 1764–1777.

[28] Y. Chen, M. Chen, Y. Liu, et al., “BAFF Promotes Follicular Helper T Cell Development and Germinal Center Formation Through BR3 Signal,” JCI Insight 9, no. 21 (2024): e183400.

[29] Y. Chen, R. Liang, X. Shi, et al., “Targeting Kinase ITK Treats Autoimmune Arthritis via Orchestrating T Cell Differentiation and Function,” Biomedicine & Pharmacotherapy 169 (2023): 115886.

[30] M. Chen, X. Lin, Y. Liu, et al., “The Function of BAFF on T Helper Cells in Autoimmunity,” Cytokine & Growth Factor Reviews 25, no. 3 (2014): 301–305.

[31] L. Yang and S. G. Zheng, “Role of Regulatory T Cells in Inflammatory Liver Diseases,” Autoimmunity Reviews 24, no. 6 (2025): 103806.

[32] X. Zhang, N. Olsen, and S. G. Zheng, “The Progress and Prospect of Regulatory T Cells in Autoimmune Diseases,” Journal of Autoimmunity 111 (2020): 102461.

[33] M. L. Kapsenberg, “Dendritic-Cell Control of Pathogen-Driven T-Cell Polarization,” Nature Reviews Immunology 3, no. 12 (2003): 984–993.

[34] J. L. Silva-Filho, C. Caruso-Neves, and A. A. S. Pinheiro, “IL-4: An Important Cytokine in Determining the Fate of T Cells,” Biophysical Reviews 6, no. 1 (2014): 111–118.

[35] P. Muranski and N. P. Restifo, “Essentials of Th17 Cell Commitment and Plasticity,” Blood 121, no. 13 (2013): 2402–2414.

[36] H. Wang, C. Li, G. Ren, et al., “Updated Insight Into the Role of Th2-Associated Immunity in Systemic Lupus Erythematosus,” Autoimmunity Reviews 22, no. 1 (2023): 103213.

[37] M. Bonelli, J. S. Smolen, and C. Scheinecker, “Treg and Lupus,” Annals of the Rheumatic Diseases 69, no. S1 (2010): i65–i66.

[38] B. D. Bell, M. Kitajima, R. P. Larson, et al., “The Transcription Factor STAT5 Is Critical in Dendritic Cells for the Development of TH2 but Not TH1 Responses,” Nature Immunology 14, no. 4 (2013): 364–371.

[39] H. S. Li, C. Y. Yang, K. C. Nallaparaju, et al., “The Signal Transducers STAT5 and STAT3 Control Expression of Id2 and E2-2 During Dendritic Cell Development,” Blood 120, no. 22 (2012): 4363–4373.

[40] R. K. Perez, M. G. Gordon, M. Subramaniam, et al., “Single-Cell RNA-seq Reveals Cell Type-Specific Molecular and Genetic Associations to Lupus,” Science 376, no. 6589 (2022): eabf1970.

[41] A. Schlitzer, V. Sivakamasundari, J. Chen, et al., “Identification of cDC1- and cDC2-Committed DC Progenitors Reveals Early Lineage Priming at the Common DC Progenitor Stage in the Bone Marrow,” Nature Immunology 16, no. 7 (2015): 718–728.

[42] C. C. Brown, H. Gudjonson, Y. Pritykin, et al., “Transcriptional Basis of Mouse and Human Dendritic Cell Heterogeneity,” Cell 179, no. 4 (2019): 846–863.

[43] L. Heger, T. P. Hofer, V. Bigley, et al., “Subsets of CD1c+ DCs: Dendritic Cell Versus Monocyte Lineage,” Frontiers in Immunology 11 (2020): 559166.

[44] E. N. Chini, C. C. Chini, V. Nin, and C. Escande, “Deleted in Breast Cancer-1 (DBC-1) in the Interface Between Metabolism, Aging and Cancer,” Bioscience Reports 33, no. 4 (2013): e00058.

[45] Q. Fang, J. A. Bellanti, and S. G. Zheng, “Advances on the Role of the Deleted in Breast Cancer (DBC1) in Cancer and Autoimmune Diseases,” Journal of Leukocyte Biology 109, no. 2 (2021): 449–454.

[46] S. Kong, M. Thiruppathi, Q. Qiu, et al., “DBC1 is a Suppressor of B Cell Activation by Negatively Regulating Alternative NF-κB Transcriptional Activity,” Journal of Immunology 193, no. 11 (2014): 5515–5524.

[47] Y. Tai, Q. Wang, H. Korner, L. Zhang, and W. Wei, “Molecular Mechanisms of T Cells Activation by Dendritic Cells in Autoimmune Diseases,” Frontiers in Pharmacology 9 (2018): 642.

[48] J. Banchereau, V. Pascual, and A. K. Palucka, “Autoimmunity Through Cytokine-Induced Dendritic Cell Activation,” Immunity 20, no. 5 (2004): 539–550.

[49] M. Son, S. J. Kim, and B. Diamond, “SLE-Associated Risk Factors Affect DC Function,” Immunological Reviews 269, no. 1 (2016): 100–117.

[50] X. Wang, X. Wu, B. Tan, et al., “Allogeneic CD19-Targeted CAR-T Therapy in Patients With Severe Myositis and Systemic Sclerosis,” Cell 187, no. 18 (2024): 4890–4904.

[51] H. Zhao, Z. Wen, and S. Xiong, “Activated Lymphocyte-Derived DNA Drives Glucose Metabolic Adaptation for Inducing Macrophage Inflammatory Response in Systemic Lupus Erythematosus,” Cells 12, no. 16 (2023): 2093.

[52] M. Gonzalez-Juarrero, T. S. Shim, A. Kipnis, A. P. Junqueira-Kipnis, and I. M. Orme, “Dynamics of Macrophage Cell Populations During Murine Pulmonary Tuberculosis,” Journal of Immunology 171, no. 6 (2003): 3128–3135.

[53] S. Geng, H. Matsushima, T. Okamoto, et al., “Emergence, Origin, and Function of Neutrophil-Dendritic Cell Hybrids in Experimentally Induced Inflammatory Lesions in Mice,” Blood 121, no. 10 (2013): 1690–1700.

[54] M.-L. Golinski, M. Demeules, C. Derambure, et al., “CD11c+ B Cells Are Mainly Memory Cells, Precursors of Antibody Secreting Cells in Healthy Donors,” Frontiers in Immunology 11 (2020): 32.

[55] H. Zhou, X. Zhao, R. Zhang, M. Miao, W. Pei, and Z. Li, “Low-Dose IL-2 Mitigates Glucocorticoid-Induced Treg Impairment and Promotes Improvement of SLE,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 141.

[56] M. Miao, X. Xiao, J. Tian, et al., “Therapeutic Potential of Targeting Tfr/Tfh Cell Balance by Low-Dose-IL-2 in Active SLE: A Post Hoc Analysis From a Double-Blind RCT Study,” Arthritis Research & Therapy 23, no. 1 (2021): 167.

[57] S. Cohen, J. S. Beebe, V. Chindalore, et al., “A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Dose Escalation Study to Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of PF-06835375, a C-X-C Chemokine Receptor Type 5 Directed Antibody, in Patients With Systemic Lupus Erythematosus or Rheumatoid Arthritis,” Arthritis Research & Therapy 26, no. 1 (2024): 117.

[58] H. Ko, C. J. Kim, and S. H. Im, “T Helper 2-Associated Immunity in the Pathogenesis of Systemic Lupus Erythematosus,” Frontiers in Immunology 13 (2022): 866549.

[59] D. A. Lebman and R. L. Coffman, “Interleukin 4 Causes Isotype Switching to IgE in T Cell-Stimulated Clonal B Cell Cultures,” Journal of Experimental Medicine 168, no. 3 (1988): 853–862.

[60] J. M. Purkerson and P. C. Isakson, “Interleukin 5 (IL-5) Provides a Signal That Is Required in Addition to IL-4 for Isotype Switching to Immunoglobulin (Ig) G1 and IgE,” Journal of Experimental Medicine 175, no. 4 (1992): 973–982.

[61] J. Henault, J. M. Riggs, J. L. Karnell, et al., “Self-Reactive IgE Exacerbates Interferon Responses Associated With Autoimmunity,” Nature Immunology 17, no. 2 (2016): 196–203.

[62] O. Elkayam, R. Tamir, A. I. Pick, and A. Wysenbeek, “Serum IgE Concentrations, Disease Activity, and Atopic Disorders in Systemic Lupus Erythematosus,” Allergy 50, no. 1 (1995): 94–96.

[63] N. Charles, D. Hardwick, E. Daugas, G. G. Illei, and J. Rivera, “Basophils and the T Helper 2 Environment Can Promote the Development of Lupus Nephritis,” Nature Medicine 16, no. 6 (2010): 701–707.

[64] C. J. Kim, C.-G. Lee, J.-Y. Jung, et al., “The Transcription Factor Ets1 Suppresses T Follicular Helper Type 2 Cell Differentiation to Halt the Onset of Systemic Lupus Erythematosus,” Immunity 49, no. 6 (2018): 272.

[65] Y. Zhou, X. Leng, H. Li, et al., “Tolerogenic Dendritic Cells Induced by BD750 Ameliorate Proinflammatory T Cell Responses and Experimental Autoimmune Encephalitis in Mice,” Molecular Medicine 23 (2017): 204–214.

[66] X. Lu, P. Jin, Q. Tang, M. Zhou, H. Xu, and C. Su, “NAD+ Metabolism Reprogramming Drives SIRT1-Dependent Deacetylation Inducing PD-L1 Nuclear Localization in Cervical Cancer,” Advanced Science 12, no. 15 (2025): e2412109.

[67] S. A. Oh, D.-C. Wu, J. Cheung, et al., “PD-L1 Expression by Dendritic Cells Is a Key Regulator of T-Cell Immunity in Cancer,” Nature Cancer 1, no. 7 (2020): 681–691.

[68] S. G. Zheng, J. D. Gray, K. Ohtsuka, S. Yamagiwa, and D. A. Horwitz, “Generation Ex Vivo of TGF-Beta-Producing Regulatory T Cells From CD4+ CD25- Precursors,” Journal of Immunology 169, no. 8 (2002): 4183–4189.

[69] J. Lu, Y. Yue, and S. Xiong, “Extracellular HMGB1 Augments Macrophage Inflammation by Facilitating the Endosomal Accumulation of ALD-DNA via TLR2/4-Mediated Endocytosis,” Biochimica et Biophysica Acta – Molecular Basis of Disease 1867, no. 10 (2021): 166184.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.